Literature DB >> 23068971

Plasma exchange in cryptogenic new onset refractory status epilepticus.

Judy Li1, Christina Saldivar, Rama K Maganti.   

Abstract

OBJECTIVE: New onset refractory status epilepticus (NORSE) is a recently described entity and has been difficult to treat because the etiology is often cryptogenic. Our aim in each case was to stop status epilepticus while simultaneously searching for the etiology.
METHODS: We describe three patients who presented with NORSE, who were refractory to multiple anticonvulsants and general anesthetics for at least 5 days. All patients had an extensive evaluation including MRI brain, CSF studies, radiologic scans for malignancy and serological autoimmune and infectious investigations.
RESULTS: Each patient responded dramatically to the use of plasma exchange therapy with cessation of status epilepticus by the fourth day of treatment. Although an etiology was sought after, no appropriate cause for NORSE could be found.
CONCLUSION: We propose early use of plasma exchange therapy (Class IV evidence) in hopes to prevent the complications of status epilepticus and prolonged hospitalization.
Copyright © 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23068971     DOI: 10.1016/j.seizure.2012.09.011

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  11 in total

1.  New-onset refractory status epilepticus: Etiology, clinical features, and outcome.

Authors:  Nicolas Gaspard; Brandon P Foreman; Vincent Alvarez; Christian Cabrera Kang; John C Probasco; Amy C Jongeling; Emma Meyers; Alyssa Espinera; Kevin F Haas; Sarah E Schmitt; Elizabeth E Gerard; Teneille Gofton; Peter W Kaplan; Jong W Lee; Benjamin Legros; Jerzy P Szaflarski; Brandon M Westover; Suzette M LaRoche; Lawrence J Hirsch
Journal:  Neurology       Date:  2015-08-21       Impact factor: 9.910

2.  Plasma Exchange as a Therapeutic Modality in a Rare Case of Cryptogenic New Onset Refractory Status Epilepticus (NORSE).

Authors:  Manisha Shrivastava; Smita Chouhan; Seema Navaid
Journal:  J Clin Diagn Res       Date:  2017-07-01

3.  Autoimmune status epilepticus.

Authors:  Carla Lopinto-Khoury; Michael R Sperling
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

Review 4.  Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.

Authors:  Marianna Spatola; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

5.  Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE.

Authors:  Dongmei Wang; Yongming Wu; Yue Pan; Shengnan Wang; Guanghui Liu; Yibo Gao; Kaibiao Xu
Journal:  Mol Neurobiol       Date:  2022-10-12       Impact factor: 5.682

Review 6.  Progress in autoimmune epileptic encephalitis.

Authors:  Sukhvir Wright; Angela Vincent
Journal:  Curr Opin Neurol       Date:  2016-04       Impact factor: 5.710

7.  Claustrum damage and refractory status epilepticus following febrile illness.

Authors:  Stefano Meletti; Jana Slonkova; Iva Mareckova; Giulia Monti; Nicola Specchio; Petr Hon; Giada Giovannini; Vaclav Marcian; Annalisa Chiari; Petr Krupa; Nicola Pietrafusa; Dagmar Berankova; Michal Bar
Journal:  Neurology       Date:  2015-09-04       Impact factor: 9.910

8.  New-Onset Refractory Status Epilepticus with Claustrum Damage: Definition of the Clinical and Neuroimaging Features.

Authors:  Stefano Meletti; Giada Giovannini; Giuseppe d'Orsi; Lisa Toran; Giulia Monti; Rahul Guha; Andreas Kiryttopoulos; Maria Grazia Pascarella; Tommaso Martino; Haris Alexopoulos; Martha Spilioti; Jana Slonkova
Journal:  Front Neurol       Date:  2017-03-27       Impact factor: 4.003

Review 9.  Updates in Refractory Status Epilepticus.

Authors:  Rohit Marawar; Maysaa Basha; Advait Mahulikar; Aaron Desai; Kushak Suchdev; Aashit Shah
Journal:  Crit Care Res Pract       Date:  2018-05-08

10.  A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE).

Authors:  Satoshi Kodama; Noritoshi Arai; Akiyoshi Hagiwara; Akio Kimura; Sousuke Takeuchi
Journal:  J Intensive Care       Date:  2018-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.